This study is for adults with advanced non-small cell lung cancer (NSCLC). It compares two treatments: one with a mix of N-803, tislelizumab, and docetaxel, and another with only docetaxel. NSCLC is a type of lung cancer that's hard to treat when it spreads.
The study is "randomized," meaning participants are put in groups by chance, and "open-label," so everyone knows the treatment given. Participants must be 18 or older, have specific cancer traits, and be able to attend study visits. They must have had a certain type of treatment before and agree to use birth control.
People can't join if they have certain diseases, infections, or allergies, or if they're pregnant. They must have good organ function and not be on certain medications. This study helps researchers understand if adding N-803 and tislelizumab makes treatment better.
- The study requires regular visits and follow-ups.
- Participants could be in either the experimental or control group.
- Participants need to meet specific health criteria to join.